ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Prime Medicine (PRME)
Prime Medicine stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$4.35▲ +20.50%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Prime Medicine in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Prime Medicine
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Prime Medicine a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $3.53 and $4.99; in 9 out of 10, between $2.60 and $6.77. Estimated annual volatility is 104%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $541M
- 52-week high
- $5.11
- 52-week low
- $2.67
- Revenue (12 months)
- $4.1M
- Revenue growth (YoY)
- +55.3%
- Gross margin
- 0.0%
- Return on equity
- -373.3%
- Free cash flow (12 months)
- $-75.8M
- Beta
- 2.35
What this means
ATLAS does not publish a fair value for PRME right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks PRME has traded between $2.67 and $5.11. Today it is 14.9% below that high and 63% above its low.
Its beta is 2.35: it tends to move more than the market, both up and down.
About the company
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA.
Want to see everything about Prime Medicine?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Prime Medicine do?
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA.
What is the chance PRME goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, PRME ends the month between $3.53 and $4.99.
How big is Prime Medicine and what is its P/E ratio?
Prime Medicine's market capitalization is $541M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is PRME?
ATLAS estimates annual volatility at 104%. In a typical month, half of the outcomes end between $3.53 and $4.99.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer